http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
TESARO (TSRO) Announces Immuno-Oncology Data Presentations at SITC
-
TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting
-
TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting
-
TESARO Announces Third-Quarter 2018 Operating Results
-
TESARO Announces Third-Quarter 2018 Operating Results
-
The Foundation for Women’s Cancer and TESARO Partner on the Race to End Women’s Cancer for 3rd Year
-
The Foundation for Women’s Cancer and TESARO Partner on the Race to End Women’s Cancer for 3rd Year
-
TESARO and Actress Cobie Smulders Launch Not on My Watch, a National Movement to Empower the Ovarian Cancer Community
-
TESARO and Actress Cobie Smulders Launch Not on My Watch, a National Movement to Empower the Ovarian Cancer Community
-
TESARO (TSRO) Reports Updated Phase 1 GARNET Data of TSR-042 (anti-PD-1 antibody) in Patients with Recurrent or Advanced MSI-H
-
TESARO Announces Data Presentations at ESMO 2018 Congress
-
TESARO Announces Data Presentations at ESMO 2018 Congress
-
TESARO to Announce Third-Quarter 2018 Financial Results on November 1, 2018
-
TESARO to Announce Third-Quarter 2018 Financial Results on November 1, 2018
-
TESARO (TSRO) Announces Data Presentations at ESMO
-
TESARO Announces Data Presentations at the ESMO 2018 Congress
-
TESARO Announces Data Presentations at the ESMO 2018 Congress
-
TESARO Announces Data Presentations at the SITC 2018 Annual Meeting
-
TESARO Announces Data Presentations at the SITC 2018 Annual Meeting
-
TESARO Announces Participation at Two Investor Conferences
-
TESARO Announces Participation at Two Investor Conferences
-
TESARO Announces Participation at Three Investor Conferences
-
TESARO Announces Participation at Three Investor Conferences
-
TESARO Announces Second-Quarter 2018 Operating Results
-
TESARO Announces Second-Quarter 2018 Operating Results
-
TESARO to Announce Second-Quarter 2018 Financial Results on August 2, 2018
-
TESARO to Announce Second-Quarter 2018 Financial Results on August 2, 2018
-
TESARO Partners With the Pan-Mass Challenge for 2018 Ride Benefiting Dana-Farber Cancer Institute
-
TESARO Partners With the Pan-Mass Challenge for 2018 Ride Benefiting Dana-Farber Cancer Institute
-
TESARO (TSRO) Draws $200 Million From Second Tranche of Non-Dilutive Term Loan Financing
-
TESARO Draws $200 Million From Second Tranche of Non-Dilutive Term Loan Financing
-
TESARO Draws $200 Million From Second Tranche of Non-Dilutive Term Loan Financing
-
TESARO (TSRO) Enters Asset Purchase Agreement with TerSera Therapeutics LLC for VARUBI in U.S. and Canada
-
TESARO Enters Asset Purchase Agreement with TerSera® Therapeutics LLC for VARUBI® in the U.S. and Canada
-
TESARO Enters Asset Purchase Agreement with TerSera® Therapeutics LLC for VARUBI® in the U.S. and Canada
-
TESARO (TSRO) Announces Collaboration to Evaluate ZEJULA in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer
-
TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer
-
TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer
-
TESARO (TSRO) Highlights TOPACIO and QUADRA Trial Results Presented at 2018 ASCO Annual Meeting
-
TESARO Summarizes TOPACIO and QUADRA Trial Results Presented at 2018 ASCO Annual Meeting
-
TESARO Summarizes TOPACIO and QUADRA Trial Results Presented at 2018 ASCO Annual Meeting
-
TESARO (TSRO) Reports Addition of ZEJULA to Cancer Drugs Fund in UK
-
TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
-
TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
-
TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
-
TESARO (TSRO) Announces Presentations of Abstracts at ASCO
-
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
-
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
-
TESARO Announces First-Quarter 2018 Operating Results
-
TESARO Announces First-Quarter 2018 Operating Results

